Could a 6-Month pill combo beat Drug-Resistant TB?

NCT ID NCT07198685

Not yet recruiting Disease control Sponsor: Wuhan Pulmonary Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 6-month combination of four drugs (bedaquiline, delamanid, linezolid, and levofloxacin) works as well as the standard longer treatment for drug-resistant tuberculosis. Fifty-two adults in Hubei, China will be randomly assigned to either the short or standard regimen. The goal is to see if the shorter treatment is safe and effective enough to replace the current long course.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of bedaquiline, delamanid, linezolid, and levofloxacin
What this could lead to: If successful, this could offer a shorter, all-oral treatment option for drug-resistant tuberculosis, reducing the burden of long-term therapy.
What could go wrong: This is a small, early-stage study in one Chinese province, so results may not apply broadly. The shorter regimen might be less effective or have unexpected side effects compared to standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multidrug-resistant tuberculosis rifampicin-resistant tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREAT TO TARGET TREATMENT DURATION

More trials for these conditions

Other studies related to the condition(s) this trial covers.